Buzzing Stocks: Honeywell International Inc. (NYSE:HON), Sinclair Broadcast Group Inc. (NASDAQ:SBGI), Allergan, Inc. (NYSE:AGN)
Dallas, Texas, 09/29/2014 (ustrademedia) – Honeywell International Inc. (NYSE:HON) sings an agreement with Tata Power SED, a defense engineering unit of Tata Power Co. Ltd. As part of this agreement, Tata will produce Honeywell’s TALIN navigator in India. The U.S. Company will license the design and hardware to test and build the production kits for TALIN in India. The agreement could be viewed in line with India’s push for local manufacturing of defense equipment. India, the world’s largest arm importer, is looking forward to modernizing its armed forces while promoting domestic industry. The agreement was announced during Indian Prime Minister’s visit to the U.S.
Sinclair Broadcast Group Inc. (NASDAQ:SBGI) today announced that its Sinclair Networks division signs syndication agreements with 41 companies for expanding distribution of its ASN (American Sports Network) initiative. The agreements allow the company to expand ASN’s college sports events distribution to 67 non-Sinclair television markets. The combined footprint for ASN is now estimated to reach 83 million households for select games. Sinclair also announced multi-year sports rights and content development agreement with the WAC (Western Athletic Conference). Sinclair also announced the launch of the ASN website www.americansportsnet.com which will showcase ASN’s gaming schedules, live scores and game highlights.
Allergan, Inc. (NYSE:AGN) today announced the U.S. FDA approval for its OZURDEX® SR (0.7 mg) biodegradable steroid implant. OZURDEX® was approved in June 2014 as a treatment for diabetic macular edema. However, the June approval was limited for patients scheduled for cataract surgery or having an artificial lens implant. Today’s announcement extends the use of OZURDEX® even for general DME patient population. Allergan’s Executive Vice President for R&D and Chief Scientific Officer, Scott M. Whitcup expressed that the company is committed to developing therapies to address unmet patient needs. The updated indication will allow the use of OZURDEX® for more patients with DME.